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Abstract
Background: The recommended starting dose of eribulin in patients with hepatic impairment is based on the
Child-Pugh score, largely informed by a pharmacokinetic study of 18 patients. In the pivotal studies of eribulin in
metastatic breast cancer (Study 301 and Study 305 [EMBRACE]), entry criteria and dose modifications were based
on liver-function test (LFT) results rather than Child-Pugh score. In populations such as patients with metastatic
breast cancer, in which metastatic infiltration is the predominant cause of hepatic impairment, using Child-Pugh
score may be problematic; in clinical practice, it has been more common for oncologists to make dosing
decisions based on LFTs. To address this, the effects of abnormal baseline LFT results on eribulin efficacy and
safety were investigated.
Methods: In this pooled post hoc analysis, 1062 patients who were randomized to receive eribulin in Studies 301
and 305 were divided into 4 groups: (A) no elevated LFT results (no liver impairment); (B) increased levels of
aspartate aminotransferase and/or alanine aminotransferase; (C) decreased albumin and/or increased levels of
aspartate aminotransferase and/or alanine aminotransferase but not increased bilirubin; and (D) increased
bilirubin. Patients were subcategorized by presence of liver metastasis. Drug exposure, dose intensity, and
treatment-emergent adverse events (TEAEs) were analyzed.
Results: Eribulin mesylate mean dosage was 0.82 (group A)–0.65 mg/m2/week (group D). Group D had shorter
treatment, more dose reductions/delays, more TEAEs leading to dose modifications, and numerically lower
objective response rates and clinical benefit rates versus groups A–C. TEAE rates leading to dose modification
were similar between group D (45.5%) and groups A–C (range, 43.5–54.9%) in the absence of liver metastases,
but higher in group D (91.3%) compared with groups A–C (range, 41.7–54.3%) if liver metastases were present.
Conclusions: Mild elevations in bilirubin levels were associated with increased toxicity and a greater requirement
for dose modifications. Based both on these study data and existing recommendations, we propose a novel
scheme to guide initial dose selection in patients with metastatic breast cancer and hepatic impairment that is
based on LFTs rather than Child-Pugh score.
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Introduction
Eribulin, an inhibitor of microtubule dynamics [1–3], has
demonstrated antitumor activity in metastatic breast can-
cer (MBC) in two randomized phase 3 trials. In previously
treated (2–5 chemotherapeutic regimens in EMBRACE/
Study 305 [NCT00388726] and ≤ 3 chemotherapeutic
regimens in Study 301 [NCT00337103]) women with
MBC, EMBRACE demonstrated that eribulin significantly
improved overall survival (OS) versus physician’s choice of
treatment [4], whereas Study 301 did not demonstrate that
eribulin was superior to capecitabine with regard to OS
[5]. As a result of these studies (Study 305 in the USA;
Studies 305 and 301 in the European Union), eribulin is
approved for the treatment of patients with MBC who
previously received ≥ 1 (European Union) or ≥ 2 (USA)
prior chemotherapies for the treatment of MBC, including
an anthracycline and a taxane in the adjuvant or meta-
static setting [6, 7].
The main route of elimination of eribulin is via biliary
excretion [8]. Although eribulin seems to be metabolized
by CYP3A4 in vitro [9], it is excreted predominately as un-
changed drug in patients [8]. Because eribulin features
hepatic excretion and metastatic disease commonly
involves the liver, the pharmacokinetics (PK) of eribulin in
18 patients with solid tumors and hepatic impairment
were assessed [10]. In this study, patients were divided
into 1 of 3 groups: normal liver function, abnormal liver
function and Child-Pugh class A, or abnormal liver
function and Child-Pugh class B. The eribulin dose was
based on the patient’s Child-Pugh class. Patients who had
normal hepatic function received eribulin mesylate 1.4
mg/m2 (equivalent to eribulin 1.23mg/m2 [expressed as
free base]) whereas patients who were classified as Child-
Pugh class A or B received a reduced starting dose of 1.1
mg/m2 and 0.7mg/m2, respectively. Compared with
patients who had normal liver function, mean dose-
normalized area under the curve from zero to infinity
(AUC0-∞) was 1.75-fold (90% CI 1.15–2.66) higher in
patients classified as Child-Pugh class A and 2.48-fold
(90% CI 1.57–3.92) higher in patients classified as Child-
Pugh class B [10]. Based on this study, a reduced eribulin
dosage is recommended for Child-Pugh class A or B
hepatic impairment (1.1 mg/m2 or 0.7 mg/m2 of eribulin
mesylate, respectively, equivalent to eribulin 0.97mg/m2
and 0.62mg/m2 [expressed as free base]) [6, 7].
The Child-Pugh score—derived from clinical and
biochemical features—was developed to assess the
prognosis in patients with chronic liver disease [11, 12].
The score was not designed, and is not validated, for de-
ciding the dose of systemic cancer therapies in patients
with liver dysfunction in the context of metastatic can-
cer. The European Medicines Agency (EMA) and US
Food and Drug Administration (FDA) have noted the
lack of biomarkers available for categorizing liver
impairment with respect to effects on drug PK and have
therefore created guidance on the use of Child-Pugh
scores [13, 14]. An important caveat in this guidance is
that the abnormalities in factors comprising the Child-
Pugh score should be directly attributable to liver dys-
function and not to an alternative cause; however, in the
context of MBC, this distinction may not be readily evi-
dent. As such, the challenges of dose selection for anti-
cancer drugs in the setting of hepatic impairment are
widely recognized [15].
In clinical practice, dosing decisions for chemother-
apeutic agents that are metabolized or cleared via the
liver are generally based on baseline liver-function
test (LFT) results rather than Child-Pugh score. Of
note, inclusion criteria regarding hepatic function
within Studies 301 and 305 were defined by levels of
total bilirubin and transaminases and not Child-Pugh
score. However, no published data are available re-
garding the relationship between LFT findings and
the efficacy and safety of eribulin. As such, this ana-
lysis of pooled efficacy and safety data based on baseline
LFT results was undertaken.
Materials and methods
Studies
This retrospective, post hoc, pooled analysis used data
from 2 prospective studies of eribulin in MBC [4, 5].
In Study 305/EMBRACE, women with locally recur-
rent disease or MBC (2–5 previous chemotherapy
regimens, including an anthracycline and a taxane)
were randomly assigned 2:1 to eribulin mesylate 1.4
mg/m2 intravenously (equivalent to 1.23 mg/m2
eribulin [expressed as free base]) on days 1 and 8
every 21 days or a treatment of the physician’s choice
[4]. To be eligible, patients were required to have
adequate liver function in screening blood tests as
evidenced by bilirubin levels ≤ 1.5 times the upper
limits of normal (ULN) and alkaline phosphatase
(AP), alanine aminotransferase (ALT), and aspartate
aminotransferase (AST) levels ≤ 3 × ULN (in the case
of liver metastases ≤ 5 × ULN). If bone metastases
were present, liver-specific AP was separated from
the total and used to assess liver-function instead of
total AP.
In Study 301, patients with MBC (≤ 3 prior chemo-
therapy regimens, of which ≤ 2 were for advanced or
metastatic disease, and prior therapy with an anthracy-
cline and a taxane) were randomly assigned 1:1 to
eribulin mesylate 1.4 mg/m2 intravenously (equivalent to
1.23 mg/m2 eribulin [expressed as free base]) on days 1
and 8 of each 21-day cycle versus capecitabine 1.25 g/m2
twice daily on days 1–14 of each 21-day cycle as first-,
second-, or third-line chemotherapy for advanced breast
cancer [5]. Adequate liver function was defined as per
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Study 305, except in the case of bone metastases, in
which liver-specific AP was ≤ 3 × ULN. Both studies re-
quired patients to have an Eastern Cooperative Oncol-
ogy Group performance status of 0–2.
Both Study 301 and Study 305 were conducted in
accordance with local laws, the Declaration of Helsinki,
and the International Conference on Harmonization
Good Clinical Practice guidelines, and with the approval
of each Institutional Review Board. All patients provided
written informed consent.
Pooled analysis
Pooled data from eribulin-treated patients in Study
301 and Study 305 [16] were analyzed by liver
impairment subgroups. Liver impairment was defined
using the Common Terminology Criteria for Adverse
Events (CTCAE) as an increased baseline level (≥ grade 1)
of bilirubin, ALT, or AST levels or a decreased baseline
level of albumin. Patients were then allocated to 1 of 4
subgroups: group A (no liver impairment), group B
(increased AST and/or ALT levels only), group C
(decreased albumin and/or increased AST, and/or ALT
levels but not increased bilirubin), and group D
(increased bilirubin). Liver involvement was defined as
presence of target or non-target liver lesions at baseline.
Safety analyses included drug exposure, dose intensity,
and dose modification (i.e., dose interruptions, reduc-
tions, and delays). Treatment-emergent adverse events
(TEAEs) by CTCAE grade and TEAEs leading to dose
modification were assessed. TEAE terms were coded
using Medical Dictionary for Drug Regulatory Affairs,
version 14.1, and graded using CTCAE, version 3.0.
Absolute neutrophil count, change from baseline, and
neutrophil/granulocyte CTCAE grade by visit were also
evaluated. The safety population comprised patients who
received any dose of study drug and was used to
summarize the safety data.
OS data were summarized using the intent-to-treat
(ITT) population (all randomized patients). Median
OS in months and 1-, 2-, and 3-year survival rates
(and 95% CIs) were calculated using Kaplan-Meier
estimate and Greenwood’s formula. Tumor assess-
ment data were summarized using the ITT popula-
tion from Study 301, plus the evaluable population
from Study 305 (all patients with measurable disease).
This population was used to calculate the point esti-
mates and 2-sided 95% CIs using the exact Clopper-
Pearson method for objective response rate (ORR; de-
fined as complete response [CR] + partial response
[PR]) and clinical benefit rate (CBR; defined as CR +
PR + stable disease ≥ 6 months). Summaries of ORR
and CBR were based on tumor response data from
independent review.
Results
Clinicopathologic and liver impairment data
Overall patient demographics and baseline disease
characteristics for the pooled analysis have been pub-
lished elsewhere [16]. In the safety population, this
post hoc analysis included patients at baseline with
normal LFTs (AST/ALT, albumin and bilirubin) (group
A; n = 540), increased AST and/or ALT levels only
(group B; n = 292), increased AST and/or ALT and/or
decreased albumin levels (group C; n = 440), and in-
creased bilirubin (group D; n = 34). The following
values are the number of patients with and without
metastatic liver involvement, respectively, by group:
group A (n = 204 and n = 336), group B (n = 210 and
n = 82), group C (n = 294 and n = 146), and group D
(n = 23 and n = 11).
In the ITT population, additional patients were in-
cluded in groups A–D: patients with no liver impairment
(group A, n = 546), increased AST and/or ALT levels
only (group B, n = 294), any abnormality except increased
bilirubin (group C, n = 443), and increased bilirubin
(group D, n = 34).
Exposure
The planned eribulin mesylate dosage intensity was
0.933 mg/m2/week. The mean actual dosage intensity
was 0.82 mg/m2/week for group A, 0.78 mg/m2/week for
both groups B and C, and 0.65 mg/m2/week for group D
(Table 1). The dosage intensity remained similar for
each liver impairment group when analyzed by meta-
static liver involvement (Supplementary Table S1).
Specifically, in patients with no liver involvement, dosage
intensity ranged from 0.81 mg/m2/week for group A to
0.67 mg/m2/week for group D and in patients with liver
involvement, dosage intensity was 0.83 mg/m2/week for
group A to 0.64 mg/m2/week for group D.
Compared with patients in group A, patients in group
D received treatment for a shorter time (mean duration
of treatment: 166 vs 129 days, respectively), and a larger
percentage of patients experienced dose reductions
(26.1% vs 61.8%, respectively) or dose delays (41.3% vs
67.7%, respectively) (Table 1). These same trends were
also observed when eribulin exposure was analyzed by
whether liver involvement was present. In patients with
no liver involvement, dose delays were experienced by
41.7% of patients in group A and 54.6% of patients in
group D, and dose reductions were experienced by
27.7% and 54.6% of patients in groups A and D, respect-
ively (Supplementary Table S1). For patients with liver
involvement, dose delays and reductions, respectively,
were experienced by 40.7% and 23.5% of patients in
group A and by 73.9% and 65.2% of patients in group D
(Supplementary Table S1).
Macpherson et al. Breast Cancer Research           (2021) 23:33 Page 3 of 9
Safety
TEAEs were experienced by ≥ 95% of patients in all
groups (Supplementary Table S2). The most commonly
reported TEAEs (occurring in ≥ 30% of patients in any
group) were neutropenia, alopecia, nausea, and leucopenia
(Supplementary Table S2). Among patients in groups A,
B, C, and D, total TEAEs leading to dose modifications
occurred in 42.8%, 54.5%, 52.5%, and 76.5% of patients re-
spectively; grade 3 or 4 TEAEs leading to dose modifica-
tions were reported in 32.6%, 42.1%, 41.8%, and 70.6% of
patients, respectively (Table 2). Patients in group D had a
higher incidence of grade ≥ 3 TEAEs leading to dose
modification than patients in group A, B, or C. The most
common TEAEs leading to dose reduction or delay were
neutropenia and leukopenia, which were more common
among patients in group D (58.8% and 17.7%, respectively)
compared with all other groups (Table 2). Among patients
in groups A, B, C, and D, febrile neutropenia leading to
dose modifications occurred in 2%, 2%, 3%, and 6% of pa-
tients, respectively. Although the sample size in group D
was small (n = 34), liver involvement appeared to change
the pattern of TEAEs that led to dose modifications. The
number of patients with TEAEs leading to dose modifica-
tions was similar across groups within the subset of pa-
tients without liver involvement (group A: 43.5%; group B:
54.9%; group C: 52.7%; group D: 45.5%). However, for pa-
tients with liver involvement, the number of TEAEs lead-
ing to dose modifications were markedly higher in those
with elevated bilirubin compared with other groups
(group A: 41.7%; group B: 54.3%; group C: 52.4%; group
D: 91.3%; Supplementary Table S3).
In all groups, the number of patients experiencing
neutrophil/granulocyte counts of grade ≥ 1 TEAEs was
29% to 39% on day 8 of cycle 1, and reduced to 14 to
22% on day 8 of subsequent treatment cycles (Supple-
mentary Table S4).
Table 1 Eribulin mesylate exposure and dose modifications in patients with liver impairment (safety population)









Bilirubin, μmol/L, median (range) 8.55 (1.6, 19.9) 8.55 (1.7, 21.0) 8.55 (1.7, 23.9) 22.70 (16.0, 75.2)
AST, U/L, median (range) 23.0 (2.6, 48.0) 51.0 (9.6, 323.0) 47.0 (9.2, 369.0) 55.0 (16.0, 474.0)
ALT, U/L, median (range) 19.0 (1.3, 51.0) 45.5 (5.0, 407.0) 39.0 (5.0, 407.0) 36.0 (12.0, 220.0)
Albumin, g/L, median (range) 42.0 (29.0, 66.0) 41.2 (31.0, 58.9) 39.0 (18.0, 58.9) 42.0 (28.0, 63.3)
Mean duration of treatment, days (SD) 166.12 (163.44) 151.65 (122.50) 140.26 (113.30) 128.76 (75.90)
Median number of cycles completed on study (range) 6.0 (1.0, 65.0) 6.0 (1.0, 38.0) 5.0 (1.0, 38.0) 4.5 (1.0, 15.0)
Mean actual dose intensity of eribulin mesylate, mg/m2/week (SD) 0.82 (0.14) 0.78 (0.16) 0.78 (0.16) 0.65 (0.18)
Patients with a dose delay, n (%) 223 (41.3) 141 (48.3) 212 (48.2) 23 (67.7)
Patients with a dose reduction, n (%) 141 (26.1) 101 (34.6) 153 (34.8) 21 (61.8)
an = 33 for mean actual dose intensity analyses
Group A, no liver impairment; group B, increased AST and/or ALT only; group C, any abnormality except increased bilirubin; group D, increased bilirubin
ALT, alanine aminotransferase; AST, aspartate aminotransferase; SD, standard deviation
Table 2 Number of patients experiencing TEAEs leading to dose modifications (reductions, delays, or interruptions) by CTCAE grade,
and occurring in > 10% of patients in any group (safety population)
Normal Liver impairment








Total 231 (42.8) 159 (54.5) 231 (52.5) 26 (76.5)
Grade 1 8 (1.5) 11 (3.8) 13 (3.0) 2 (5.9)
Grade 2 47 (8.7) 25 (8.6) 34 (7.7) 0
Grade 3 111 (20.6) 76 (26.0) 114 (25.9) 10 (29.4)
Grade 4 65 (12.0) 47 (16.1) 70 (15.9) 14 (41.2)
Neutropenia 125 (23.2) 91 (31.2) 132 (30.0) 20 (58.8)
Leucopenia 44 (8.2) 26 (8.9) 39 (8.9) 6 (17.7)
Group A, no liver impairment; group B, increased AST and/or ALT only; group C, any abnormality except increased bilirubin; group D, increased bilirubin
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTCAE, Common Terminology Criteria for Adverse Events; TEAE, treatment-emergent adverse event
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Efficacy
ORR was 11.6% in group A, 14.0% in group B, and
12.7% in group C (Table 3). CBR was 27.2% in group A,
24.6% in group B, and 22.2% in group C (Table 3). How-
ever, the group with an increased bilirubin at baseline
(group D) was associated with numerically lower ORR
(0%) and CBR (19%) compared with all other groups
(Table 3). The median OS was numerically lower in
patients with liver impairment (13.2, 12.3, and 12.3
months in groups B, C, and D, respectively) com-
pared with patients without liver impairment (group
A: 17.5 months; Supplementary Table S5). OS in pa-
tient subgroups by liver involvement is summarized
in Supplementary Table S6.
Discussion
Results from this retrospective, post hoc analysis of
pooled data on eribulin suggest that even mild elevations
in bilirubin at baseline were associated with a reduction
in dose intensity, more frequent early-dose reduction,
and a higher proportion of grades 3 and 4 toxicity, com-
pared with patients with normal LFT results and those
solely with increases in levels of transaminases and/or
decreased albumin. This was evident despite study-entry
criteria limiting enrolment to patients with bilirubin no
greater than 1.5 times upper limit of normal. Although
these results are based on a relatively small number of
patients, the data are consistent with, and can be
explained by, the published PK and pharmacology data
for eribulin. In vivo studies have shown that eribulin’s
CYP3A4 metabolism is of limited contribution, as
evidenced by the observation that coadministration of
eribulin with a CYP3A4 inhibitor or inducer has no
effect on its exposure or systemic clearance [17–19], as
well as the predominant excretion of eribulin as
unchanged drug. Pooled data from 513 eribulin-treated
patients have shown that eribulin clearance decreased
with increasing AP and bilirubin [20], which is consist-
ent with eribulin’s known biliary route of excretion [8].
Taken together, disruption or obstruction to the biliary
tree, as indicated by an elevated bilirubin, is likely to lead
to impaired excretion of eribulin with increased AUC
and greater toxicity with subsequent impact on the
delivery of dosage intensity. In this analysis, we focused
on bilirubin alone because the etiology of raised AP may
be difficult to determine in a population with a high
incidence of skeletal metastases. The current guidance
regarding eribulin dosing in MBC is based on Child-
Pugh score and derived from a relatively small PK study
of 18 patients with advanced cancer [10]. Within this
study, the median bilirubin level in the Child-Pugh class
A group was similar to the normal liver-function group;
however, 42% of patients in this group had an additional
hepatic pathology, and all had liver metastasis. The
impact of these hepatic pathologies on the PK findings
within the Child-Pugh class A group is not clear and
cannot be discounted or ascertained from the data pre-
sented. Higher levels of baseline bilirubin were present
within the Child-Pugh class B group, and this may ex-
plain some of the observed PK differences between
group A and group B [10]. Of note, Child-Pugh criteria
were not used in any of the phase 3 eribulin studies as
part of the assessments for study entry—these studies
used baseline LFT parameters [4, 5]. Given these data,
Table 3 Response rates in patients with liver impairment (independent review)
Normal Liver impairment








CR 3 (0.6) 1 (0.4) 1 (0.2) 0
PR 59 (11.1) 39 (13.7) 53 (12.5) 0
SD 275 (51.6) 141 (49.5) 199 (46.9) 24 (75.0)
Progressive disease 165 (31.0) 82 (28.8) 137 (32.3) 6 (18.8)
Not evaluable 6 (1.1) 10 (3.5) 16 (3.8) 1 (3.1)
Unknowna 25 (4.7) 12 (4.2) 18 (4.2) 1 (3.1)
Objective response rate (CR + PR) 62 (11.6) 40 (14.0) 54 (12.7) 0
95% CIb (9.0, 14.7) (10.2, 18.6) (9.7, 16.3) (0, 10.9)
Clinical benefit rate (CR + PR + SDc) 145 (27.2) 70 (24.6) 94 (22.2) 6 (18.8)
95% CIb (23.5, 31.2) (19.7, 30.0) (18.3, 26.4) (7.2, 36.4)
aPatients who had no baseline scans or only baseline scans
bExact Clopper-Pearson 2-sided CI
cFor clinical benefit, SD must be at least 6 months
Group A, no liver impairment; group B, increased AST and/or ALT only; group C, any abnormality except increased bilirubin; group D, increased bilirubin
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; CR, complete response; PR, partial response; SD, stable disease
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we have explored dosing decisions based on bilirubin
level and the presence of liver metastasis rather than
Child-Pugh criteria.
Of specific concern, the Child-Pugh score was devel-
oped to evaluate operative risk in patients with chronic
liver disease; however, the Child-Pugh score is now com-
monly used as a prognostic tool in these patients [12].
Despite having several limitations, the Child-Pugh score
is described in EMA and FDA guidance as a method-
ology for assessing hepatic function for the evaluation of
the PK of medicinal products [13, 14]. The EMA recog-
nizes that the Child-Pugh criteria were not developed
for the purpose of predicting drug-elimination capacity,
and if this criteria is used, researchers must ensure that
patients included in the study have an adequate range of
decrease in serum albumin and increase in serum biliru-
bin and prothrombin time [13].
In patients with solid tumors, abnormal liver function
is often caused by metastatic disease. For example,
whereas the incidence of cirrhotic liver disease in the
population with breast cancer is relatively low (e.g., 0.3%
in American women with breast cancer aged ≥ 66 years)
[21], metastatic spread to the liver is common, with liver
involvement present in approximately 25% of women
presenting with metastatic disease [22]. Within this
population, the use of Child-Pugh score is problematic
and is likely to lead to inconsistencies in dose selection
with the potential for over- or under-treatment. As clear
guidance is lacking as to when the Child-Pugh score
should be calculated in routine oncological practice, its
application may be arbitrary. Because an individual with
normal liver parameters would be allocated to Child-
Pugh class A, an inappropriately low starting dose, as
recommended within the prescribing information for
Child-Pugh class A, may then be administered. Further-
more, mechanistically distinct types of liver pathology
may influence drug metabolism in diverse ways. For
example, in PK studies with gefitinib, patients with
moderate and severe hepatic impairment due to liver
metastases had no clinically relevant differences in drug
exposure; patients characterized as Child-Pugh class B
and C secondary to cirrhosis, however, had a significant
increase in gefitinib exposure [23]. In this analysis,
we observed a numerically higher rate of grade 3/4
treatment-emergent adverse events requiring eribulin
dose modification in patients with raised bilirubin
levels in the presence of liver metastases (19/23, 86%)
than in patients with raised bilirubin and no liver
metastases (5/11, 45%).
Concerns have been raised regarding the use of Child-
Pugh criteria to guide dosing in patients with metastatic
cancer [24]. As such, an alternative system based on
LFTs such as the National Cancer Institute–Organ
Dysfunction Working Group (NCI-ODWG) [25] may be
more relevant. The NCI-ODWG criteria are based on
levels of bilirubin and AST. Increased bilirubin up to 1.5
times upper limit of normal or AST greater than the
upper limit of normal would categorize a patient as hav-
ing mild hepatic dysfunction and this correlates with
Child-Pugh class A [25]. However, the equal weighting
applied by this score to bilirubin and AST in defining
mild hepatic dysfunction may not be appropriate for a
drug such as eribulin that is eliminated by biliary excre-
tion as unchanged drug. Our data suggest that a patient
allocated to the NCI-ODWG mild category because they
have elevated bilirubin levels has a substantial chance of
toxicity and dose reduction. On the other hand, a patient
allocated to the same group because of raised AST levels
most likely does not.
Some limitations of this analysis are that it is retrospect-
ive, the subgroup of patients with elevated bilirubin was
small (n = 34), and the studies did not collect relevant
clinical and biochemical data to enable calculation of
Child-Pugh score, precluding a comparison between
bilirubin levels and Child-Pugh classes. Additionally, the
efficacy data presented in this study should be interpreted
with caution as results may have been impacted by factors
that were not accounted for in the study, such as the vol-
ume of liver disease and previous lines of therapy.
Despite its limitations, this analysis suggests the need
for improved guidance regarding eribulin dosing in pa-
tients with liver impairment. As such, we propose a dos-
ing scheme based on the following: (1) the entry criteria
for Studies 305 and 301, (2) dose modifications defined
within the study protocols and the Summary of Product
Characteristics, and (3) pooled LFT data from this ana-
lysis (Table 4). This guidance may be more aligned with
clinical practice than guidance based on Child-Pugh
criteria; however, it is unproven in a real-world setting.
Moreover, this scheme was developed based on a rela-
tively small sample size. As such, additional investigation
will be necessary to validate this proposed scheme.
Conclusions
This post hoc pooled analysis of LFT data from 1062 pa-
tients enrolled in Studies 301 and 305 provides evidence
that elevated bilirubin levels at baseline are associated with
a reduction in dose and actual dose intensity of eribulin, a
higher proportion of grade 3 and 4 toxicities, and a nu-
merically lower ORR. These findings highlight a need for
caution regarding the dosing of eribulin in patients with
bilirubin levels outside the normal range. Currently, the
guidance for dosing eribulin in patients with hepatic im-
pairment is based on the Child-Pugh criteria; however,
there are limitations to using this approach in patients
with cancer. Here, we propose an alternative dosing
schema for eribulin which is based on information con-
tained within the protocols for Studies 301 and 305 and
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Table 4 Proposed Macpherson-Palmieri dosing scheme for eribulin mesylate
Initial dosing
Clinical definition Dosing recommendations
Group 1 Adequate liver functiona 1.4 mg/m2 (equivalent to 1.23 mg/m2
eribulin [expressed as free base])
Group 2 Bilirubin level: > ULN ≤ 1.5 × ULN 1.1 mg/m2
Group 3 Bilirubin level: > 1.5 × ULN or ALT/AST: ≥ 3 × ULN (for liver metastases, ALT/AST: ≥ 5 × ULN) 0.7 mg/m2 b
Subsequent dosing: day 8
Clinical finding Dosing modification
Group 1 ANC < 1.0 × 109/L and/or platelet count < 75 × 109/L; or nonhematological AE > grade 2c Postpone treatment until recovery
Group 2 ANC < 1.0 × 109/L and/or platelet count < 75 × 109/L; or nonhematological AE > grade 2c Postpone treatment until recovery
Group 3 ANC < 1.0 × 109/L and/or platelet count < 75 × 109/L; or nonhematological AE > grade 2c Postpone treatment; omit day 8
Recovery on day 15 or earlier
Clinical action Dosing modification
Group 1 Resume treatment on the day that recovery is observed (considered new day 8 of cycle) 1.1 mg/m2
Group 2 Resume treatment on the day that recovery is observed (considered new day 8 of cycle) 0.7 mg/m2
Recovery after day 15
Clinical action Dosing modification
Group 1 Omit day 8 and resume scheduled treatment on day 1 of next cycle 1.1 mg/m2
Group 2 Omit day 8 and resume scheduled treatment on day 1 of next cycle 0.7 mg/m2
Special considerations:
• Grade 4 neutropenia > 7 days
• Grade 3/4 neutropenia with fever or infection requiring treatment with growth factors
and/or antibiotics
• Grade 4 thrombocytopenia
• Grade 3 thrombocytopenia requiring platelet and/or blood transfusion
• Nonhematologic grade 3–4 toxicities
Clinical action Dosing modification
Group 1 Resume treatment on day 1 of next cycle 1.1 mg/m2
Group 2 Resume treatment on day 1 of next cycle 0.7 mg/m2
Group 3 Consider stopping treatment
with eribulin mesylate
Dose escalationd
Clinical action Dose modification
Group 2
and 3
If, following cycle 1 day 1 and cycle 1 day 8, there are no toxicity issues (especially hematological
toxicities determined by ANC and platelets), consider increasing dose at the start of the next cycle
Refer to day 8 of this table to assess hematological and nonhematological toxicities at the next
dose level; reduce dose if necessary
Next dose level
This dosing scheme is the work of investigators (IM and CP). These unproven recommendations require further study; dosing recommendations are based on
eribulin mesylate unless otherwise specified
aDefined as bilirubin ≤ ULN and AP, ALT, and AST ≤ 3 × ULN (in the presence of liver metastases: ≤ 5 × ULN); unless there are bone metastases, in which case liver-
specific AP must be separated from the total and used to assess the liver function instead of the total AP. If AP is > 3 × ULN (in absence of liver metastases) or >
5 × ULN (in presence of liver metastases) and patient also is known to have bone metastases, the liver-specific AP must be separated from the total and used to
assess the liver function instead of the total AP
bThere are no data for this group given that such patients were excluded from the study. Given the lack of clinical data, extreme caution should be applied to the
use of eribulin within this group and clinical judgment should be used. If eribulin is used, then close monitoring for toxicities is required
cExcept inadequately treated nausea and/or vomiting
dTo be considered when treatment was initiated at a lower starting dose
AE, adverse event; ALT, alanine transaminase; ANC, absolute neutrophil count; AP, alkaline phosphatase; AST, aspartate transaminase; ULN, upper limit of normal
Macpherson et al. Breast Cancer Research           (2021) 23:33 Page 7 of 9
the Summary of Product Characteristics, as well as the
current pooled analysis of LFT data. While this dosing
schema does require further validation, it is more reflect-
ive of the information used within pivotal metastatic
breast cancer studies with regard to liver function and
eribulin dosing.
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